These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 28342317)
1. High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer. Sikic D; Breyer J; Hartmann A; Burger M; Erben P; Denzinger S; Eckstein M; Stöhr R; Wach S; Wullich B; Keck B; Wirtz RM; Otto W Transl Oncol; 2017 Jun; 10(3):340-345. PubMed ID: 28342317 [TBL] [Abstract][Full Text] [Related]
2. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A; Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276 [TBL] [Abstract][Full Text] [Related]
3. High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer. Sikic D; Taubert H; Wirtz RM; Breyer J; Eckstein M; Weyerer V; Kubon J; Erben P; Bolenz C; Burger M; Hartmann A; Wullich B; Wach S; Keck B Life (Basel); 2021 Jun; 11(7):. PubMed ID: 34209360 [TBL] [Abstract][Full Text] [Related]
4. Prediction of recurrence of non-muscle invasive bladder cancer: The role of androgen receptor and miRNA-2909. Muzaail HH; El-Assmy A; Harraz AM; Awadalla A; Shokeir AA; Abdel-Aziz AF Urol Oncol; 2022 May; 40(5):197.e25-197.e35. PubMed ID: 35430138 [TBL] [Abstract][Full Text] [Related]
5. FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer. Breyer J; Wirtz RM; Erben P; Rinaldetti S; Worst TS; Stoehr R; Eckstein M; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W BJU Int; 2019 Jan; 123(1):187-196. PubMed ID: 30120861 [TBL] [Abstract][Full Text] [Related]
6. High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. Breyer J; Wirtz RM; Otto W; Erben P; Worst TS; Stoehr R; Eckstein M; Denzinger S; Burger M; Hartmann A Cancer Immunol Immunother; 2018 Mar; 67(3):403-412. PubMed ID: 29150702 [TBL] [Abstract][Full Text] [Related]
7. Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer. Yasui M; Kawahara T; Izumi K; Yao M; Ishiguro Y; Ishiguro H; Uemura H; Miyoshi Y BMC Cancer; 2019 Apr; 19(1):331. PubMed ID: 30961575 [TBL] [Abstract][Full Text] [Related]
8. The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer. Sikic D; Taubert H; Breyer J; Eckstein M; Weyerer V; Keck B; Kubon J; Otto W; Worst TS; Kriegmair MC; Erben P; Hartmann A; Wullich B; Wirtz RM; Wach S Cancer Manag Res; 2021; 13():6567-6578. PubMed ID: 34447272 [TBL] [Abstract][Full Text] [Related]
9. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer. Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041 [TBL] [Abstract][Full Text] [Related]
10. Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC). Nicklas AP; Kramer MW; Serth J; Hennenlotter J; Hupe MC; Reimer DU; Stenzl A; Merseburger AS; Kuczyk MA; von Klot CJ Adv Ther; 2018 Nov; 35(11):2054-2068. PubMed ID: 30232708 [TBL] [Abstract][Full Text] [Related]
11. ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ. Breyer J; Otto W; Wirtz RM; Wullich B; Keck B; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Laible M; Schlombs K; Eidt S; Denzinger S; Burger M; Hartmann A; Urol Int; 2017; 98(3):282-289. PubMed ID: 27992871 [TBL] [Abstract][Full Text] [Related]
12. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of Ecke TH; Kiani A; Schlomm T; Friedersdorff F; Rabien A; Jung K; Kilic E; Boström P; Tervahartiala M; Taimen P; Gleichenhagen J; Johnen G; Brüning T; Koch S; Roggisch J; Wirtz RM Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050010 [TBL] [Abstract][Full Text] [Related]
13. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience. Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376 [TBL] [Abstract][Full Text] [Related]
14. Androgen Receptor Predicts First and Multiple Recurrences in Non-Muscle Invasive Urothelial Carcinoma of the Bladder. Yonekura S; Terauchi F; Hoshi K; Yamaguchi T; Kawai S Pathol Oncol Res; 2019 Jul; 25(3):987-994. PubMed ID: 29862474 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Role of mRNA-Expression of Aquaporins (AQP) 3, 4, 7 and 9 in Stage pT1 Non-Muscle-Invasive Bladder Cancer. Reiß J; Kälble S; Bründl J; Rosenhammer B; Gierth M; Weber F; Eckstein M; Wirtz RM; Denzinger S; Burger M; Otto W; Breyer J Bladder Cancer; 2021; 7(1):71-78. PubMed ID: 38993218 [TBL] [Abstract][Full Text] [Related]
16. Risk Factors Predictive of Recurrence and Progression for Patients Who Suffered Initial Recurrence After Transurethral Resection of Stage pT1 Bladder Tumor in Chinese Population: A Retrospective Study. Shen Z; Xie L; Chen T; Tian D; Liu X; Xu H; Zhang Y; Wu Z; Sha N; Xing C; Ding N; Hu H; Wu C Medicine (Baltimore); 2016 Feb; 95(5):e2625. PubMed ID: 26844474 [TBL] [Abstract][Full Text] [Related]
17. Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer. Otto W; Rubenwolf PC; Burger M; Fritsche HM; Rößler W; May M; Hartmann A; Hofstädter F; Wieland WF; Denzinger S BMC Cancer; 2012 Oct; 12():459. PubMed ID: 23043286 [TBL] [Abstract][Full Text] [Related]
18. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC. Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660 [TBL] [Abstract][Full Text] [Related]
19. Loss of CHEK2 Predicts Progression in Stage pT1 Non-Muscle-Invasive Bladder Cancer (NMIBC). Spachmann PJ; Azzolina V; Weber F; Evert M; Eckstein M; Denzinger S; Burger M; Otto W; Breyer J Pathol Oncol Res; 2020 Jul; 26(3):1625-1632. PubMed ID: 31506803 [TBL] [Abstract][Full Text] [Related]
20. High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer. Sikic D; Eckstein M; Weyerer V; Kubon J; Breyer J; Roghmann F; Kunath F; Keck B; Erben P; Hartmann A; Wirtz RM; Wullich B; Taubert H; Wach S Urol Oncol; 2022 Feb; 40(2):63.e9-63.e18. PubMed ID: 34330652 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]